{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-26-000068","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2026-06-29T15:14:38+00:00","discovered_at":"2026-06-29T15:16:01.668828+00:00","generated_at":"2026-06-29T15:16:14.472262+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Emergent BioSolutions secures $52.7M contract modification from ASPR for ACAM2000 supply","bullets":["$52.7M modification exercises Option Year 7 under existing 10-year ASPR contract.","Deliveries of ACAM2000 vaccine, ancillaries, and diluent begin June 2026; diluent balance by December 2026.","Contract supports U.S. government smallpox and mpox preparedness and response needs.","Modification follows recent ACAM2000 approvals for mpox in Saudi Arabia and Singapore."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-26-000068","json":"https://secwatch.observer/filing/0001367644-26-000068.json","markdown":"https://secwatch.observer/filing/0001367644-26-000068.md","text":"https://secwatch.observer/filing/0001367644-26-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000068/0001367644-26-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000068/ebs-20260626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T15:16:14.472262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}